2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its holdings in shares of 2seventy bio, Inc. (NASDAQ:TSVT) by 20.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 27,315 shares of the company’s stock after buying an additional 4,715 shares during the period. SG Americas Securities LLC’s holdings in 2seventy bio were worth $117,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Exchange Traded Concepts LLC lifted its holdings in 2seventy bio by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 34,616 shares of the company’s stock worth $148,000 after buying an additional 8,778 shares in the last quarter. Deutsche Bank AG lifted its holdings in 2seventy bio by 15.7% in the 3rd quarter. Deutsche Bank AG now owns 26,134 shares of the company’s stock worth $102,000 after buying an additional 3,537 shares in the last quarter. Public Employees Retirement System of Ohio lifted its holdings in 2seventy bio by 112.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 84,757 shares of the company’s stock worth $332,000 after buying an additional 44,895 shares in the last quarter. Vanguard Group Inc. lifted its holdings in 2seventy bio by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,733,877 shares of the company’s stock worth $14,637,000 after buying an additional 256,203 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in 2seventy bio by 4.0% in the 3rd quarter. Wellington Management Group LLP now owns 2,994,471 shares of the company’s stock worth $11,738,000 after buying an additional 114,549 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

2seventy bio Stock Performance

TSVT opened at $4.64 on Friday. 2seventy bio, Inc. has a 1-year low of $1.53 and a 1-year high of $12.69. The company has a 50-day moving average of $5.21 and a 200-day moving average of $4.01. The company has a market capitalization of $238.08 million, a P/E ratio of -1.05 and a beta of 1.84.

2seventy bio (NASDAQ:TSVT) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($1.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.11. 2seventy bio had a negative net margin of 216.73% and a negative return on equity of 59.19%. The business had revenue of $10.68 million during the quarter, compared to the consensus estimate of $13.91 million. During the same quarter in the prior year, the firm earned ($0.60) EPS. As a group, sell-side analysts expect that 2seventy bio, Inc. will post -1.39 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on TSVT shares. Wedbush reiterated a “neutral” rating and issued a $5.00 price objective on shares of 2seventy bio in a report on Monday, March 18th. SVB Leerink upgraded shares of 2seventy bio from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $5.00 to $18.00 in a report on Wednesday, January 31st. Leerink Partnrs upgraded shares of 2seventy bio from a “market perform” rating to an “outperform” rating in a report on Wednesday, January 31st. TD Cowen reiterated a “market perform” rating on shares of 2seventy bio in a report on Wednesday, January 31st. Finally, Citigroup boosted their target price on shares of 2seventy bio from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, 2seventy bio currently has an average rating of “Hold” and a consensus target price of $13.17.

Insider Activity at 2seventy bio

In other 2seventy bio news, Director Casdin Capital, Llc acquired 300,000 shares of the stock in a transaction that occurred on Thursday, March 21st. The stock was acquired at an average price of $4.90 per share, with a total value of $1,470,000.00. Following the transaction, the director now directly owns 1,482,623 shares in the company, valued at $7,264,852.70. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 2.60% of the company’s stock.

2seventy bio Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.